Keywords : anti obesity drug, Drug , serotonin, Orlistat, Vaccine, phentermine, Rimonabant
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. The report profiles 59 companies including many key and niche players such as Arena Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Orexigen Therapeutics, I...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. The report profiles 59 companies including many key and niche players such as Arena Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Orexigen Therapeutics, Inc., and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Global Drug And Medication Industry
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
2. INDUSTRY OVERVIEW 4
Market Yet to Unlock Potential 4
Obesity: An Unmet Medical Need 4
Obesity - A Global Epidemic 5
Table 1: Leading Countries by Percentage of Obese Population
(2010) (includes corresponding Graph/Chart) 6
Table 2: Obesity Rates (%) in OECD Countries (includes
corresponding Graph/Chart) 7
Table 3: Obese and Overweight & Obese Population in the World
(2010): Percentage Share Breakdown by Region for US, European
Union, and Rest of World (includes corresponding Graph/Chart) 8
Table 4: Abdominal Obesity Prevalence (%) by Region and Sex
(includes corresponding Graph/Chart) 8
Trends and Issues 9
Rising Demand for Obesity Therapeutics 9
Growing Emphasis on Metabolism 9
Barriers to Development of Effective Drugs 9
New Research Aids in Discovery of Novel Drugs 10
Growing Problem of Obesity in Asia Particularly China 10
Online Drug Stores Boost Sales 10
3. COMPETITION 11
Roche Leads the Race 11
Withdrawal of High-Revenue Generating Drugs Affects
Competition Metrics 11
Table 5: Leading Brands in the Global Anti-obesity Drugs
Market (2010): Percentage Share Breakdown of Revenues for
Xenical/orlistat, Reductil/Meridia (sibutramine), Alli, and
Others (includes corresponding Graph/Chart) 12
Competition Grows with Pipeline Drugs 12
Current Anti-Obesity Drugs in Pipeline: 2011 14
4. OBESITY - AN INTRODUCTION 15
Diagnosis of Obesity 15
BMI Calculation and Classification 15
Waist Circumference and BMI 16
Causes of Obesity 16
Unhealthy Eating Habits 16
Environmental and Genetic Factors 16
Sedentary Lifestyle 16
Alcohol Intake 17
Childhood Obesity 17
Psychological Factors 17
Pregnancy 17
Hormonal Disorders 17
Drugs 17
Aging 17
Risks Associated with Obesity 18
5. OBESITY TREATMENT 19
Dietary Therapy 19
Exercise Therapy 19
Behavior Therapy 19
Pharmacotherapy 19
Weight Loss Surgery 19
Invasive Vis-à-vis Non-invasive Procedures 19
A Brief Review of Select Invasive Procedures 20
Bariatric Surgery 20
Laparoscopic Adjustable Gastric Banding 20
Vertical Banded Gastroplasty (VBG) 20
Roux-en-Y Gastric Bypass Procedure (RYGB) 20
Lap-Band Procedure 20
Gastric Band Procedure 20
Gastric Bypass Procedure 20
Doudenal Switch 21
Prescription Drugs Vis-à-vis Non-Prescription Drugs 21
Table 6: Obesity Treatment Options and Corresponding Success
Rate 21
6. ANTI-OBESITY DRUGS - AN INSIGHT 22
Introduction 22
Mechanism of Action 22
Review of Available Drugs 23
Phentermine 23
Sibutramine 23
Orlistat 23
Anti-obesity Drugs, Brands and Mechanism of Action 24
Table 7: Global Anti-obesity Prescription Drugs Market
(2010): Percentage Share Breakdown of Prescriptions by
Physician Practices - Primary Care Physicians (PCP),
Internal Medicine, Obstetrics/ Gynecology,
Endocrinology/Diabetes, Psychiatry/ Neurology, Cardiology
and Others (includes corresponding Graph/Chart) 24
Review of Select Drugs Awaiting approval / Under Trials 25
7. PRODUCT APPROVALS/LAUNCHES 27
FDA Expert Panel Recommends Approval of Orexigen’s Contrave 27
Orexigen Receives FDA Approval for Anti-Obesity Drug 27
European Commission Authorizes Sale of Orlistat without
Prescription in the UK 27
Sanofi-Aventis Receives Swiss Approval for Acomplia 27
Zydus Cadila Introduces Slimona 28
Torrent Introduces Rimoslim 28
Gencor Introduces Slimaluma 28
Orexigen Develops Excalia 28
Scripps Research Institute Develops Vaccine for Obesity 28
Sanofi-Aventis Receives Approval to Market Obesity Drug in EU 29
Sanofi-Aventis Rolls Out Acomplia 29
Sanofi Secures Approval for Acomplia in the UK 29
Novo Nordisk to Develop Anti-obesity Drug 29
Sanofi-Aventis Receives Approval to Market Acomplia in Mexico 29
Ind-Swift Introduces Sibuslim-10 30
Wellnx Launches NV 30
Iron-Tek Introduces Appetite Suppressant 30
Yamanouchi and Keio University Discover Target Molecule for
Developing Anti-obesity Drug 30
8. RECENT INDUSTRY ACTIVITY 31
Takeda Enters into Partnership with Florida Hospital and SBMRI 31
DCGI Bans Sale of R-Sibutramine and Sibutramine 31
Abbot Withdraws Meridia 31
Takeda and Amylin Halt Clinical Studies of Pramlintide/
Metreleptin Combination Therapy 32
Isis Includes ISIS-FGFR4Rx into Drug Development Pipeline 32
Arrowhead Establishes Ablaris Therapeutics 32
Orexigen Enters into Partnership with Takeda 33
Ventana and GTMC Enter into Distribution Agreement 33
Taisho and Glaxo Group Enter into an Agreement 33
PROLOR Inks Agreement with YRDCL 33
Aegis Enters into Joint Commercialization Agreement with
Albany Medical College 33
Wyeth Pharmaceuticals Acquires Thiakis 34
9. CORPORATE INITIATIVES IN THE RECENT PAST - A PERSPECTIVE BUILDER 35
Pfizer Halts CP-945, 598 Development 35
Shionogi to Acquire Sciele Pharma 35
Anthill Inks Agreement with Zafgen 35
EMEA Suspends Acomplia 35
GlaxoSmithKline to Sell Alli as OTC Drug 35
Sanofi-Aventis to Market Acomplia in UK 36
Orexigen Receives 4th US Patent for Contrave 36
BELLUS Health to Acquire Innodia 36
Ore Secures License to Develop Romazarit 36
GlaxoSmithKline Receives FDA Approval for Orlistat 36
Pfizer Receives Approval for Slentrol 37
GlaxoSmithKline Secures Licensing Rights of Orlistat 37
Pfizer Collaborates with Bristol-Myers Squibb 37
Takeda Collaborates with LG Life Sciences 37
Takeda to Acquire Paradigm 38
Sanofi-Aventis Secures Reimbursement Status for Acomplia 38
AstraZeneca Inks Agreement with Palatin Technologies 38
Switzerland Includes Acomplia in Reimbursement List 39
Allergan Pockets EndoArt 39
Sanofi-Aventis Receives Approval for Acomplia in Brazil 39
Biocon Inks MoU with Neopharma 39
Aurigene Partners with Forest Laboratories 40
Genaera Initiates First Human Trial of Trodusquemine 40
Neurogen Completes First Trial of NGD-4715 40
Alizyme Secures USFDA Approval for Cetilistat Trials 40
GW Pharma to Start Human Trials of New Anti Obesity Drug 40
Epix Completes Phase Ib Trial of PRX-07034 41
7TM Pharma Starts Phase I/II Trial of TM30339 41
Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals 41
Merck Terminates Collaboration with Nastech 41
Sanofi-Aventis to Receive Rights for Rimonabant 42
UMN Pharma Inks Agreement with Crucell and DSM Biologics 42
7TM Pharma Pockets CareX SA 42
BioLineRx Inks Licensing Agreement with Yissum 42
Arena Starts Phase III Clinical Trials of Lorcaserin 43
Drug Induced Serotonin Could Promote Weight Loss 43
Takeda Initiates Phase II Clinical Trials of ALT-962 43
Glenmark to Commence Phase I Trial of New Anti-Obesity Drug 43
Amylin-Leptin Integrated Therapy to Treat Obesity 43
Vivus Completes Phase II Trial of Qnexa 44
VERNALIS Starts Phase I trial for Obesity 44
7TM Pharma Completes Phase I/ II Clinical Trials of TM30338 44
10. FOCUS ON SELECT PLAYERS 45
Arena Pharmaceuticals, Inc. (US) 45
AstraZeneca Plc (UK) 45
F. HOFFMANN-LA ROCHE LTD. (Switzerland) 45
GlaxoSmithKline Plc (UK) 46
Orexigen Therapeutics, Inc. (US) 46
VIVUS, Inc. (US) 46
11. GLOBAL MARKET PERSPECTIVE 47
Table 8: World Recent Past, Current & Future Market Analysis
for Anti-Obesity Drugs by Geographic Region - US, Europe and
Rest of World Independently Analyzed with Annual Sales
Figures in US$ million for Years 2009 through 2017 (includes
corresponding Graph/Chart) 47
Table 9: World Historic Review for Anti-Obesity Drugs by
Geographic Region - US, Europe and Rest of World Independently
Analyzed with Annual Sales Figures in US$ million for Years
2003 through 2008 (includes corresponding Graph/Chart) 48
Table 10: World 15-Year Perspective for Anti-Obesity Drugs by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2010 and
2017 (includes corresponding Graph/Chart) 49
12. THE UNITED STATES 50
A.Market Analysis 50
Market Overview 50
Table 11: Leading Product Segments in the US Weight Loss
Market (2010): Percent Share Breakdown of Revenues for Diet
Drinks, Health Clubs, Bariatric Surgery, Diet Foods,
Artificial Sweeteners, Weight Loss Centers, Medically
Supervised Programs, Meal Replacements & Appetite
Suppressants, Prescription Drugs, Low Calorie Diet Programs
and Others (includes corresponding Graph/Chart) 50
Obesity Catching Them Young 51
Key Statistics 51
Table 12: Obesity-Affected Population in the US (2010):
Percentage Share Breakdown by Age Group (includes
corresponding Graph/Chart) 51
Table 13: Proportion (%) of Obesity in the US Overweight
Population by Age Group (includes corresponding Graph/
Chart) 52
Table 14: Obesity and Overweight Prevalence in US Adults
(2010) (includes corresponding Graph/Chart) 52
Table 15: Obesity Prevalence in US Adults by Type of
Obesity (2010) (includes corresponding Graph/Chart) 52
State-wise Stats 52
Table 16: Top 20 US States by Obesity Rate (%) (2010)
(includes corresponding Graph/Chart) 53
Table 17: US Obesity Prevalence Estimates and Forecasts
(2006-2020) (includes corresponding Graph/Chart) 54
Reimbursement Scenario 54
Regulatory Environment 54
Insufficient Regulatory and Enforcement Laws 54
Obesity and Related Ailments: Burden on Societal and
Economic Cost 55
Competition 55
Product Approval/Launches 55
Strategic Corporate Developments 57
Review of Major Players 63
B.Market Analytics 64
Table 18: US Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ million for Years 2009 through 2017
(includes corresponding Graph/Chart) 64
Table 19: US Historic Review for Anti-Obesity Drugs Market
Independently Analyzed with Annual Sales Figures in US$
million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 65
13. EUROPE 66
A.Market Analysis 66
Market Overview 66
Obese Population in Europe 66
Table 20: Obese and Overweight & Obese Population in the
European Union (2010): Percentage Share Breakdown by Age
Group (includes corresponding Graph/Chart) 67
Table 21: Select EU Member Countries Ranked by Obesity
Rates (2010) (includes corresponding Graph/Chart) 67
Table 22: Obesity Prevalence Rates (%) Among Adults by
Gender (2010) (includes corresponding Graph/Chart) 68
Childhood Obesity Rates in EU 69
Focus on Select Players 69
B.Market Analytics 71
Table 23: European Recent Past, Current & Future Analysis
for Anti-Obesity Drugs by Geographic Region/Country -
France, Germany, Italy, UK and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2009 through 2017 (includes corresponding
Graph/Chart) 71
Table 24: European Historic Review for Anti-Obesity Drugs by
Geographic Region/Country - France, Germany, Italy, UK and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 72
Table 25: European 15-Year Perspective for Anti-Obesity
Drugs by Geographic Region/Country - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2003, 2010 and 2017 (includes
corresponding Graph/Chart) 73
13a. FRANCE 74
A.Market Analysis 74
Market Overview 74
Changing Lifestyle Alter Health Profile 74
Strategic Corporate Developments 74
B.Market Analytics 76
Table 26: French Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 76
Table 27: French Historic Review for Anti-Obesity Drugs
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 77
13b. GERMANY 78
Market Analysis 78
Table 28: German Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 78
Table 29: German Historic Review for Anti-Obesity Drugs
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 79
13c. ITALY 80
Market Analysis 80
Table 30: Italian Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 80
Table 31: Italian Historic Review for Anti-Obesity Drugs
Market Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 81
13d. THE UNITED KINGDOM 82
A.Market Analysis 82
Market Overview 82
Strategic Corporate Developments 83
B.Market Analytics 84
Table 32: UK Recent Past, Current & Future Analysis for
Anti-Obesity Drugs Market Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) 84
Table 33: UK Historic Review for Anti-Obesity Drugs Market
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 85
13e. REST OF EUROPE 86
A.Market Analysis 86
Review of Select Markets 86
Spain 86
Belgium 86
The Netherlands 86
Finland 87
Sweden 87
Strategic Corporate Developments 87
B.Market Analytics 88
Table 34: Rest of Europe Recent Past, Current & Future
Analysis for Anti-Obesity Drugs Market Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 88
Table 35: Rest of Europe Historic Review for Anti-Obesity
Drugs Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 89
14. REST OF WORLD 90
A.Market Analysis 90
Brief Review of Select Regions 90
Asia-Pacific 90
Australia 90
Table 36: Prevalence Rate (%) of overweight/ obese
Students in Australia (includes corresponding
Graph/Chart) 91
China 91
India 92
Drugs Under Development by Indian Companies 92
Japan 92
Takeda Pharmaceutical Company Limited - A Key Player 92
Korea 93
Use of Diet Pills Lack Proper Monitoring 93
New Zealand 93
Strategic Corporate Developments 93
B.Market Analytics 99
Table 37: Rest of World Recent Past, Current & Future
Analysis for Anti-Obesity Drugs Market Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) 99
Table 38: Rest of World Historic Review for Anti- Obesity
Drugs Market Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) 100
COMPETITIVE LANDSCAPE
Total Companies Profiled: 59 (including Divisions/Subsidiaries - 67)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 27
Canada 1
Japan 3
Europe 17
France 2
The United Kingdom 5
Italy 1
Rest of Europe 9
Asia-Pacific (Excluding Japan) 18
Middel East 1
------------------------------------------
